L-Dopa treatment in Parkinson's Disease.
D000367:Age Factors; D000856:Anorexia Nervosa / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007989:Libido; D008297:Male; D008598:Menstruation; D001523:Mental Disorders / Q000139:chemically induced; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000378:metabolism; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D014839:Vomiting / Q000139:chemically induced
D010276:Parasympatholytics; D010648:Phenylacetates; D004295:Dihydroxyphenylalanine; D004298:Dopamine